2012
The Role of Hypoxia and Hypoxia-Inducible Factor-1Alpha in Preeclampsia Pathogenesis
Tal R. The Role of Hypoxia and Hypoxia-Inducible Factor-1Alpha in Preeclampsia Pathogenesis. Biology Of Reproduction 2012, 87: 134, 1-8. PMID: 23034156, DOI: 10.1095/biolreprod.112.102723.Peer-Reviewed Original ResearchConceptsSoluble fms-like tyrosine kinase-1Pathogenesis of preeclampsiaRole of hypoxiaSoluble endoglinAngiotensin II receptor type IFms-like tyrosine kinase-1Spiral artery remodelingTyrosine kinase-1Hypoxia-inducible factor-1alphaReceptor type IHypoxia-inducible factorMaternal manifestationsPutative culpritsFetal morbiditySymptomatic therapyArtery remodelingPlacental hypoxiaCascade of eventsEndothelin-1Preeclampsia pathogenesisDisease manifestationsPossible molecular linkPreeclampsiaEffective preventionPathogenesis
2008
Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration.
Tal R, Shaish A, Rofe K, Feige E, Varda-Bloom N, Afek A, Barshack I, Bangio L, Hodish I, Greenberger S, Peled M, Breitbart E, Harats D. Endothelial-targeted gene transfer of hypoxia-inducible factor-1alpha augments ischemic neovascularization following systemic administration. Molecular Therapy 2008, 16: 1927-36. PMID: 18797451, DOI: 10.1038/mt.2008.191.Peer-Reviewed Original ResearchConceptsHypoxia-inducible factor-1alphaSystemic administrationTherapeutic efficacyProangiogenic gene therapyFactor-1alphaSystemic side effectsEnhanced blood perfusionRoute of administrationTail vein administrationHindlimb ischemia modelMouse hindlimb ischemia modelMurine preproendothelin-1 promoterClinical outcomesPreproendothelin-1 promoterC57BL/6 miceIschemic neovascularizationIntravenous routeIschemic muscleIntraarterial routeIschemia modelCapillary densityIschemic regionSide effectsSystemic toxicityTherapeutic angiogenesis
2005
Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation
Post MJ, Sato K, Murakami M, Bao J, Tirziu D, Pearlman JD, Simons M. Adenoviral PR39 improves blood flow and myocardial function in a pig model of chronic myocardial ischemia by enhancing collateral formation. AJP Regulatory Integrative And Comparative Physiology 2005, 290: r494-r500. PMID: 16254127, DOI: 10.1152/ajpregu.00460.2005.Peer-Reviewed Original ResearchConceptsChronic myocardial ischemiaCollateral formationMyocardial ischemiaBlood flowPig modelAdvanced coronary artery diseaseGrowth factorCoronary artery diseaseHypoxia-inducible factor-1alphaRegional blood flowUpregulation of VEGFDose-dependent mannerFGF receptor expressionArtery diseaseCollateral scoreIschemic myocardiumIndividual growth factorsMyocardial functionReceptor expressionReal-time PCRRegional perfusionLocal VEGFPeptide injectionAngiogenic therapyRegional functionDelayed Arteriogenesis in Hypercholesterolemic Mice
Tirziu D, Moodie KL, Zhuang ZW, Singer K, Helisch A, Dunn JF, Li W, Singh J, Simons M. Delayed Arteriogenesis in Hypercholesterolemic Mice. Circulation 2005, 112: 2501-2509. PMID: 16230502, DOI: 10.1161/circulationaha.105.542829.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApolipoprotein B-48Apolipoproteins BBlood Flow VelocityDisease Models, AnimalEndothelium, VascularFemoral ArteryHumansIn Vitro TechniquesIschemiaMagnetic Resonance ImagingMiceMice, KnockoutNeovascularization, PhysiologicOligonucleotide Array Sequence AnalysisReceptors, LDLUmbilical VeinsConceptsFemoral artery ligationControl miceLaser Doppler imagingArtery ligationTissue perfusionDay 7Doppler imagingReceptor 1Strain-matched control miceVascular cell adhesion molecule-1Monocyte/macrophage influxCell adhesion molecule-1Hypercholesterolemic low-density lipoproteinDistal limb perfusionMacrophage scavenger receptor 1Growth factor therapyIschemia-induced angiogenesisRestoration of perfusionAdhesion molecule-1Arterial blood flowHypoxia-inducible factor-1alphaLow-density lipoproteinScavenger receptor 1Controls 3 daysFactor therapy
2004
Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors
Davis DW, Shen Y, Mullani NA, Wen S, Herbst RS, O’Reilly M, Abbruzzese JL, McConkey DJ. Quantitative Analysis of Biomarkers Defines an Optimal Biological Dose for Recombinant Human Endostatin in Primary Human Tumors. Clinical Cancer Research 2004, 10: 33-42. PMID: 14734449, DOI: 10.1158/1078-0432.ccr-0736-3.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsApoptosisBiomarkersCohort StudiesDiagnostic ImagingDose-Response Relationship, DrugEndostatinsEndothelial CellsHumansHypoxia-Inducible Factor 1, alpha SubunitIn Situ Nick-End LabelingNeoplasmsNeovascularization, PathologicPlatelet Endothelial Cell Adhesion Molecule-1Proto-Oncogene Proteins c-bcl-2Recombinant ProteinsTomography, Emission-ComputedTranscription FactorsConceptsHypoxia-inducible factor-1alphaRecombinant human endostatinMicrovessel densityLaser scanning cytometryTC deathHuman endostatinPhase I dose-finding studyTerminal deoxynucleotidyl transferase-mediated nick end labeling stainingTumor cellsEndothelial cellsTumor-associated endothelial cellsSignificant clinical activityFactor-1alphaRefractory solid tumorsCohort of patientsNick end labeling stainingPhase I trialDose-finding studyTumor microvessel densityTumor blood flowOptimal biological doseEnd labeling stainingWhole tissue sectionsPositron emission tomographyPrimary human tumors
2002
Mutations in the VHL gene in sporadic apparently congenital polycythemia
Pastore Y, Jelinek J, Ang S, Guan Y, Liu E, Jedlickova K, Krishnamurti L, Prchal J. Mutations in the VHL gene in sporadic apparently congenital polycythemia. Blood 2002, 101: 1591-1595. PMID: 12393546, DOI: 10.1182/blood-2002-06-1843.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultArginineAspartic AcidBase SequenceChildChild, PreschoolDNA Mutational AnalysisErythroid Precursor CellsErythropoietinFemaleHeterozygoteHomozygoteHumansLeucineLigasesMaleMutationPedigreePolycythemiaSequence Analysis, DNATryptophanTumor Suppressor ProteinsTyrosineUbiquitin-Protein LigasesValineVon Hippel-Lindau Tumor Suppressor ProteinConceptsVon Hippel-LindauVHL geneTumor suppressor von Hippel-LindauPolycythemic disordersDownstream target genesVHL mutationsHypoxia-sensing pathwayVHL functionHypoxia-inducible factor-1alphaProteosomal degradationTarget genesErythroid cellsGermline VHL mutationsCongenital polycythemiaChuvash polycythemiaVHL syndromeGenesHIF-1alphaDevelopment of tumorsFactor-1alphaElevated serum Epo levelsMutationsEPO productionAutosomal dominant disorderPathway
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply